Vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors: development and validation of predictive 3-D QSAR models through extensive ligand- and structure-based approaches
暂无分享,去创建一个
Rino Ragno | Flavio Ballante | Adele Pirolli | Richard B. Wickersham | Alexandros Patsilinakos | Stéphanie Hesse | Enrico Perspicace | Gilbert Kirsch | Enrico Perspicace | R. Ragno | F. Ballante | S. Hesse | A. Patsilinakos | Adele Pirolli | Gilbert Kirsch | Stéphanie Hesse
[1] R. Costi,et al. Pharmacophore Assessment Through 3-D QSAR: Evaluation of the Predictive Ability on New Derivatives by the Application on a Series of Antitubercular Agents , 2013, J. Chem. Inf. Model..
[2] O. Silakari,et al. 3D-QSAR Studies of Various Diaryl Urea Derivatives of Multi-targeted Receptor Tyrosine Kinase Inhibitors: Molecular Field Analysis Approach , 2008 .
[3] Huanxiang Liu,et al. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking. , 2009, Journal of molecular graphics & modelling.
[4] W. Risau,et al. Mechanisms of angiogenesis , 1997, Nature.
[5] Mark S. Johnson,et al. ShaEP: Molecular Overlay Based on Shape and Electrostatic Potential , 2009, J. Chem. Inf. Model..
[6] Haichun Liu,et al. De novo design of N-(pyridin-4-ylmethyl)aniline derivatives as KDR inhibitors: 3D-QSAR, molecular fragment replacement, protein-ligand interaction fingerprint, and ADMET prediction , 2012, Molecular Diversity.
[7] Fabrizio Manetti,et al. HIV-reverse transcriptase inhibition: inclusion of ligand-induced fit by cross-docking studies. , 2005, Journal of medicinal chemistry.
[8] R. Hartmann,et al. CYP19 (aromatase): exploring the scaffold flexibility for novel selective inhibitors. , 2008, Bioorganic & medicinal chemistry.
[9] Huabei Zhang,et al. Combined 3D-QSAR modeling and molecular docking study on 1,4-dihydroindeno[1,2-c]pyrazoles as VEGFR-2 kinase inhibitors. , 2010, Journal of molecular graphics & modelling.
[10] Wang Zan,et al. Pharmacophore-based 3D-QSAR as a predictive method for the QSAR analysis on a series of potent and selective inhibitors for three kinases of RTK family , 2010 .
[11] P. A. Harris,et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. , 2008, Journal of medicinal chemistry.
[12] Keith T Flaherty,et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] F. Da Settimo,et al. Design, synthesis and biological evaluation of new classes of thieno[3,2-d]pyrimidinone and thieno[1,2,3]triazine as inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2). , 2013, European journal of medicinal chemistry.
[14] Bart Landuyt,et al. Vascular Endothelial Growth Factor and Angiogenesis , 2004, Pharmacological Reviews.
[15] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[16] Kenneth J. Hillan,et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer , 2004, Nature Reviews Drug Discovery.
[17] J. Folkman,et al. TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.
[18] Conrad C. Huang,et al. UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..
[19] E. Hu,et al. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit. , 2008, Journal of medicinal chemistry.
[20] Mark S. Johnson,et al. Generating Conformer Ensembles Using a Multiobjective Genetic Algorithm , 2007, J. Chem. Inf. Model..
[21] Yongchang Shi,et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.
[22] N. Ferrara,et al. Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) , 2001, The Journal of Biological Chemistry.
[23] Yadong Chen,et al. Pharmacophore Guided 3D‐QSAR CoMFA Analysis of Amino Substituted Nitrogen Heterocycle Ureas as KDR Inhibitors , 2009 .
[24] E. Scholar,et al. Role of Tyrosine Kinase Inhibitors in Cancer Therapy , 2005, Journal of Pharmacology and Experimental Therapeutics.
[25] Bikash R. Sahoo,et al. Exploring novel KDR inhibitors based on pharmaco-informatics methodology , 2013, SAR and QSAR in environmental research.
[26] Antonia Caroli,et al. Hsp90 Inhibitors, Part 1: Definition of 3-D QSAutogrid/R Models as a Tool for Virtual Screening , 2014, J. Chem. Inf. Model..
[27] Shuguang Wu,et al. Molecular docking and 3D-QSAR study on 4-(1H-indazol-4-yl) phenylamino and aminopyrazolopyridine urea derivatives as kinase insert domain receptor (KDR) inhibitors , 2012, Journal of Molecular Modeling.
[28] S. Wold,et al. PLS: Partial Least Squares Projections to Latent Structures , 1993 .
[29] R. Raychowdhury,et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. , 2009, Cancer research.
[30] M. Rajagopalan,et al. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors , 2013, Journal of enzyme inhibition and medicinal chemistry.
[31] Chris Morley,et al. Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.
[32] M. Morrison,et al. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis. , 2008, Journal of medicinal chemistry.
[33] T. Ng,et al. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[34] P. Depreux,et al. Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. , 2011, Bioorganic & medicinal chemistry letters.
[35] Neerja Kaushik-Basu,et al. Combining 3-D Quantitative Structure-Activity Relationship with Ligand Based and Structure Based Alignment Procedures for in Silico Screening of New Hepatitis C Virus NS5B Polymerase Inhibitors , 2010, J. Chem. Inf. Model..
[36] P. Hawkins,et al. Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.
[37] Mark S. Johnson,et al. Accurate conformation‐dependent molecular electrostatic potentials for high‐throughput in silico drug discovery , 2009, J. Comput. Chem..
[38] Taebo Sim,et al. Pharmacophore based 3D-QSAR study of VEGFR-2 inhibitors , 2009, Medicinal Chemistry Research.
[39] S. Rafii,et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. , 2000, The Journal of clinical investigation.
[40] Federico Corelli,et al. Hsp90 Inhibitors, Part 2: Combining Ligand-Based and Structure-Based Approaches for Virtual Screening Application , 2014, J. Chem. Inf. Model..
[41] Jans H. Alzate-Morales,et al. Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations. , 2012, Journal of molecular graphics & modelling.
[42] P. Lan,et al. Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR , 2011, Journal of enzyme inhibition and medicinal chemistry.
[43] Yutaka Maeda,et al. Novel 4-amino-furo[2,3-d]pyrimidines as Tie-2 and VEGFR2 dual inhibitors. , 2005, Bioorganic & medicinal chemistry letters.
[44] L. Claesson‐Welsh,et al. VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.
[45] P. Singh,et al. A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRα tyrosine kinase inhibitors: Derivatives of N-Phenyl-N′-{4-(4-quinolyloxy)phenyl}urea as antitumor agents , 2008, Journal of enzyme inhibition and medicinal chemistry.
[46] Elizabeth Yuriev,et al. Latest developments in molecular docking: 2010–2011 in review , 2013, Journal of molecular recognition : JMR.
[47] S. Cho,et al. Pharmacophore and docking-based combined in-silico study of KDR inhibitors. , 2009, Journal of molecular graphics & modelling.
[48] T. Bhat,et al. The Protein Data Bank and the challenge of structural genomics , 2000, Nature Structural Biology.
[49] Yuquan Wei,et al. YLT192, a Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy in Preclinical Models , 2014, Scientific Reports.
[50] Benjamin A. Ellingson,et al. Conformer Generation with OMEGA: Algorithm and Validation Using High Quality Structures from the Protein Databank and Cambridge Structural Database , 2010, J. Chem. Inf. Model..
[51] Ajay N. Jain,et al. Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.
[52] Rino Ragno,et al. 3-D QSAutogrid/R: An Alternative Procedure To Build 3-D QSAR Models. Methodologies and Applications , 2012, J. Chem. Inf. Model..
[53] Richard Kendall,et al. Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. , 2007, Journal of medicinal chemistry.